en
Scientific article
English

Glatiramer acetate treatment negatively regulates type I interferon signaling

Published inNeurology® neuroimmunology & neuroinflammation, vol. 2, no. 6, e179
Publication date2015
Abstract

Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS), promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-mediated M2 monocyte polarization.

Citation (ISO format)
MOLNARFI, Nicolas et al. Glatiramer acetate treatment negatively regulates type I interferon signaling. In: Neurology® neuroimmunology & neuroinflammation, 2015, vol. 2, n° 6, p. e179. doi: 10.1212/NXI.0000000000000179
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
ISSN of the journal2332-7812
399views
1downloads

Technical informations

Creation11/30/2016 2:38:00 PM
First validation11/30/2016 2:38:00 PM
Update time03/15/2023 1:06:01 AM
Status update03/15/2023 1:06:00 AM
Last indexation05/02/2024 6:00:39 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack